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Abstract
Background: Our research group has previously published a dosimetric planning study that demonstrated that a
60 Gy/10 fractions intralesional boost with whole-brain radiotherapy (WBRT) to 30 Gy/10 fractions was biologically
equivalent with a stereotactic radiosurgery (SRS) boost of 18 Gy/1 fraction with 30 Gy/10 fractions WBRT. Helical
tomotherapy (HT) was found to be dosimetrically equivalent to SRS in terms of target coverage and superior to
SRS in terms of normal tissue tolerance. A phase I trial has been now completed at our institution with a total of
60 enrolled patients and 48 evaluable patients. The phase II dose has been determined to be the final phase I
cohort dose of 60 Gy/10 fractions.
Methods/Design: The objective of this clinical trial is to subject the final phase I cohort dose to a phase II
assessment of the endpoints of overall survival, intracranial control (ICC) and intralesional control (ILC). We
hypothesize HT would be considered unsuitable for further study if the median OS for patients treated with the HT
SIB technique is degraded by 2 months, or the intracranial progression-free rates (ICC and ILC) are inferior by 10%
or greater compared to the expected results with treatment by whole brain plus SRS as defined by the RTOG
randomized trial. A sample size of 93 patients was calculated based on these parameters as well as the statistical
assumptions of alpha = 0.025 and beta = 0.1 due to multiple statistical testing. Secondary assessments of toxicity,
health-related quality-of-life, cognitive changes, and tumor response are also integrated into this research protocol.
Discussion: To summarize, the purpose of this phase II trial is to assess this non-invasive alternative to SRS in
terms of central nervous system (CNS) control when compared to SRS historical controls. A follow-up phase III trial
may be required depending on the results of this trial in order to definitively assess non-inferiority/superiority of
this approach. Ultimately, the purpose of this line of research is to provide patients with metastatic disease to the
brain a shorter course, dose intense, non-invasive radiation treatment with equivalent or improved CNS control/
survival and health-related quality-of-life/toxicity profile when compared to SRS radiotherapy.
Trial registration: Clinicaltrials.gov - NCT01543542.
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Background
Introduction
Historically, treatment for patients with metastatic dis-
ease in the brain has been palliative whole brain radio-
therapy (WBRT) alone. Over the last 10 years,
introduction of focal treatments (surgery or radiosur-
gery) for selected patients with metastatic disease has
been explored both in clinical trials and institutional
series. The treatment of patients with metastatic disease
to brain now may include one or more of the following
interventions: best supportive care, palliative WBRT,
radiosurgery (SRS), or surgical resection with the goals
of management being effective palliation of symptoms,
preventing intracranial progression, preserving/stabiliza-
tion of neurologic function, and maintenance of quality
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of life [1]. Typically, patients who are suitable for more
aggressive, multi-modality therapies are those with oli-
gometastatic disease (1-3 metastases), controlled extra-
cranial disease, and good performance status.
Randomized studies have demonstrated local control
and neurologic progression free survival benefits for sur-
gery or radiosurgery in conjunction with WBRT in this
population when compared to WBRT alone, radiosur-
gery, or surgery alone [2,3].
Stereotactic brain radiotherapy
Radiosurgery delivered as a single fraction to individual
intracranial lesions has been established as a safe alter-
native to surgical resection for patients with oligometa-
static disease within the brain [4-6]. The Radiation
Therapy Oncology Group (RTOG) 9502 clinical trial
established dose recommendations of 15-24 Gy for indi-
vidual lesions up to 4 cm based on observed central ner-
vous system toxicity at 3 months post treatment. This
individualized approach has subsequently been shown to
be safe and effective in numerous single institution and
multi-institution reports and trials. For example, the
multi-institutional randomized RTOG 9508 trial
reported by Andrews et al., randomized 333 patients
with 1-3 brain metastases between WBRT alone versus
WBRT plus single fraction SRS boost [7]. Patients trea-
ted with WBRT and SRS were found to have improved/
stable 6 month KPS and improved local control com-
pared to WBRT alone. For the entire patient population
a trend towards superior OS was observed in the WBRT
and SRS cohort (6.5 vs. 5.7 months, p = 0.13) with a sig-
nificant OS benefit for the subgroup of patients with
single brain metastases (6.5 vs. 4.9 months, p = 0.04).
The authors concluded that WBRT plus SRS should be
considered standard treatment for patients with single
brain metastases and considered for other patients with
2-3 brain metastases.
Conceptual framework for fractionated SRS
Logistically, radiosurgery requires separate localization
and treatment procedures that add some inconvenience
and cost for patients, providers and caregivers. Depend-
ing on the radiosurgery system used, invasive immobili-
zation devices may be necessary which can add to
patient discomfort. Single fraction treatments also do
not permit the exploitation of the potential radiobiologic
benefits of reassortment and reoxygenation that may
occur with a fractionated radiotherapy course. Hall et al.
have argued that fractionated stereotactic radiotherapy
may be more efficacious in the treatment of neoplastic
disease compared to single fraction radiosurgery [8].
Additionally, tumor cell repopulation or sublethal
damage repair may occur if there is a significant break
between the radiosurgery and whole brain radiotherapy
sessions. Finally, depending on the radiosurgery system
used, treatment of more than 3 metastases may involve
prohibitively long treatments, requiring multiple sessions
or omission of radiosurgery entirely.
The introduction of in-room image guidance systems
integrated with radiation treatment machines has led to
the introduction of minimally invasive and non-invasive
stereotactic radiosurgery/radiotherapy techniques. One
such unit, Helical tomotherapy (HT) combines intensity
modulated fan-beam radiotherapy delivery with mega-
voltage computed tomography (MVCT) imaging for
integrated patient positioning and treatment delivery
[9,10]. Such a combination provides a potential alterna-
tive to conventional stereotactic frame systems for preci-
sion radiotherapy [11]. Dosimetric evaluation of HT
delivery for primary and metastatic brain tumors have
suggested similar normal tissue sparing and target cov-
erage compared to other precision radiotherapy techni-
ques. HT (as well as other forms of intensity modulated
radiotherapy delivery) lends itself to synchronous boost
strategies as multiple targets can be easily treated to dif-
ferent dose (and dose per fraction) levels in the course
of the intensity modulated radiation delivery [12].
Therefore, HT could potentially allow for radiosur-
gery-type boost treatments to be given synchronously
with the standard whole brain radiotherapy dose and in
this way be used to efficiently boost multiple brain
metastases without the need for separate stereotactic
procedures. From a dosimetric standpoint, the ability to
incorporate boost contributions with larger field
volumes as part of the treatment planning optimization
process provides an advantage of the simultaneous
boost strategy over sequential whole brain radiotherapy
with radiosurgery boost. This advantage occurs as the
radiosurgery boost dose is added to the previously deliv-
ered whole brain dose without opportunity for optimiza-
tion of these two components potentially resulting in
unintended increased dose to the brain. In the case of
the treatment of brain metastases using the SIB techni-
que the lower isodose “spill” from the SIB can be incor-
porated as a component contributing to the whole brain
radiation dose allowing the simultaneous optimization
of both components and improved dose distribution
compared to sequential WBRT and SRS boosts.
In a discussion of linear accelerator delivery techni-
ques using fixed circular collimators, Podgorsak et al.
noted improved conformity for non-coplanar delivery
compared to single plane rotational delivery suggesting
coplanar arc approaches should be at a disadvantage
compared to conventional stereotactic non-coplanar
techniques [13]. In HT fan beam arc therapy; however,
the ability to modulate the beam intensity from multiple
(51 per rotation and multiple overlapping rotations in
the case of HT) coplanar projections helps offset the
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disadvantage of standard coplanar delivery. In compari-
sons of serial tomotherapy to gamma knife delivery [14]
and HT to conventional photon and proton stereotactic
techniques [15,16], fan beam arc therapy has been
demonstrated to provide comparable conformity with
excellent target dose homogeneity. Thus, tomotherapy
would appear to be a feasible alternative for precision
radiotherapy to small intracranial volumes.
Clearly, increased intracranial control can carry bene-
fits to the patient in terms of a decreased rate of neuro-
logic morbidity and death from progressive intracranial
disease. However, in the setting of metastatic cancer,
expected survival is limited and in the randomized trials
reported, an overall survival benefit from SRS + WBRT
or surgery + WBRT has not uniformly been noted.
From a societal point of view, it may be difficult to jus-
tify resource intense treatments such as craniotomy or
radiosurgery. Additionally from a patient point of view,
it may be difficult to justify the inconvenience and side
effects of these treatments in the face of a limited survi-
val benefit. Improvements in technology to achieve
improved intracranial disease control while minimizing
resource use and patient inconvenience are needed for
this common cancer problem. Thus, the combination of
WBRT with a synchronous boost may carry significant
therapeutic gain for the patient with brain metastases
compared to the conventional combination of WBRT
with a separate SRS boost.
Preclinical investigations/considerations
In order to calculate potentially equivalent biological
doses for fractionated radiotherapy when compared to
SRS techniques, the linear quadratic (LQ) equation is
frequently utilized for these calculations. This equation
provides a method of comparing different radiation frac-
tionation schemes according to their Biologically Effec-
tive Dose (BED):
BED = nd ∗ (1 + d/(α/β))
where n = number of fractions; d = dose/fraction; a/b
= 10 for tumour effects; 3 for late effects
The LQ equation is widely accepted as a useful tool
for comparing fractionation schemes and clinical trials
of altered fractionation based on predictions by the
model, and have confirmed its accuracy in predicting
late effects for different radiation schedules. For the pur-
poses of this study the tissue tolerances based on the
BED equivalent tissue derived from available phase I/II
and II trials of radiosurgery added to whole brain radio-
therapy for patients with brain metastases are used for
comparison. Within the RTOG 9005 radiosurgery dose
escalation protocol, metastasis in the 2-3 cm range were
treated with a radiosurgery dose of 18 Gy, while smaller
lesions were treated with doses up to 24 Gy without
toxicity [17]. Within the RTOG 9508 trial, radiosurgery
boosts of 15-20 Gy were used in addition to a WBRT of
37.5 Gy in 15 fractions for a total lesional BED dose of
159-222 Gy. Using LQ equation we calculated that with
the simultaneous infield boost technique, an intra-lesion
dose of 45- 60 Gy/10 fractions would provide a similar
intra-lesion BED range to that delivered within the
RTOG 9508 from the combination of whole brain radio-
therapy plus radiosurgery.
We modelled the feasibility of a simultaneous in field
boost (SIB) to individual brain metastases during a
course of whole brain radiotherapy using helical
tomotherapy IMRT [18]. Planning CT data from 14
patients with 1-3 brain metastases treated with conven-
tional palliative whole brain radiotherapy were used to
model an intralesional SIB delivery that provided a total
intralesional dose of 60 Gy with a surrounding whole
brain dose of 30 Gy (designed to be isoeffective to
whole brain radiotherapy of 30 Gy with an 18 Gy/1 frac-
tion radiosurgery boost). Accuracy of treatment on the
helical tomotherapy unit was verified in a phantom
using radiographic films and point dose measurements
versus calculated planning data. In all cases, SIB to 60
Gy with WBRT to 30 Gy was possible while maintaining
critical structures below assigned dose limits. Estimated
radiation delivery time for the SIB treatment was
approximately 10 minutes per fraction. Planning and
treatment of the head phantom was associated with an
overall accuracy of 2 mm. Comparison to conventional
non-co-planar arc fractionated stereotactic radiotherapy
plan demonstrated similar target coverage and improved
critical tissue sparing even for a challenging anatomy
with multiple lesions in the same plane as the optic
apparatus. Based on this modelling study, use of an
image guided SIB on HT seemed potentially feasible and
a phase I trial was initiated.
Phase I clinical trial results
Based on the preclinical dosimetric results, a phase I
clinical trial was initiated in 2006 to explore the HT SIB
brain metastases concept at three institutions (London,
Ontario (lead institution), Ottawa, Ontario and Madison,
Wisconsin) [19]. The study objective was to determine
the maximally tolerated dose (MTD) of synchronous in-
field boost (SIB) HT RT integrated with WBRT for the
palliative treatment of patients with 1-3 brain metas-
tases. The phase I trial was approved by the Institutional
Review Boards at the participating institution and regis-
tered (Ontario Cancer Clinical Trials Registry OCT
1145 TOMO-B) as per CONSORT guidelines. Patient
eligibility for the trial was as follows: histologically pro-
ven cancer, imaging and clinical presentation consistent
with brain metastases; 1-3 brain metastases on
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pretreatment contrast enhanced CT or MRI, lesion size
≥ 5 mm and ≤ 3 cm in diameter, lesion > 5 mm from
brainstem optic or optic apparatus, Karnofsky Perfor-
mance Status ≥ 70, extracranial disease absent, con-
trolled or planned to be treated (in the case of
synchronous presentation), and anticipated survival
greater than 3 months. The trial was designed according
to typical phase I dose escalation rules with 5 dose levels
for the SIB boost: 35, 45, 50, 55, and 60 Gy. The trial
was designed to accrue 3 patients at each dose level
with a subsequent escalation if no dose limiting toxicity
(DLT) was seen at 3 months with a further 3 patients to
be enrolled if one patient experienced DLT. During the
three-month waiting period for the dose level under
assessment we allowed enrolment at the previously eval-
uated dose level one step below the current dose level.
Toxicity was monitored weekly during treatment and
every month for 3 months post treatment then every 3
months for one year. Response on imaging at 12 weeks
post treatment was assessed. Patients were accrued at 3-
6 patients per dose level and escalation to the next dose
level occurs if no limiting (grade 3 or greater) toxicity
was observed in more than 1 of 3 or 2 of 6 patients by
three months post treatment. This endpoint was
designed to be similar to the RTOG 9005 radiosurgery
dose finding study. Patients were also monitored for
long-term toxicity, understanding that the treatment
paradigm being explored is novel and that important
CNS toxicity endpoints, such as radionecrosis might
manifest after the initial three-month observation point.
A total of sixty patients were registered for potential
treatment in the phase I trial. Twelve patients (20%)
were excluded from the analysis, due to treatment refu-
sal (n = 6), ineligibility to receive treatment due to
decline in performance status related to progressive dis-
ease (n = 4), or subsequent loss to follow-up after treat-
ment (n = 2). Therefore, a total of 48 (80%) treated
patients were included for the DLT analysis. The mean
age of patients on protocol was 65.0 years (range 39-90
years). Thirty (63%) patients were male and median Kar-
nofsky performance status was 80 (range 70-100). A
total of 24 (50%) of patients were diagnosed with a lung
primary (23 non-small cell lung cancer, 1 small cell lung
cancer). A total of 70 lesions were treated with 3
patients having 3 lesions, 16 patients with 2 lesions, and
29 patients with solitary lesions. Median lesion size was
1.38 cm (range 0.5-3 cm).
A total of 32/48 (66%) of cases were evaluable at three
months post treatment with imaging; 29/48 (60%) had
their planned 3 month clinical visit as well. Among the
16 (33%) cases that did not have imaging at 3 months,
reasons for non-evaluation were progressive extracranial
disease (n = 14) or early intracranial recurrence (n = 2).
Of those patients with imaging but no clinical follow-up
at 3 months (n = 3), reasons for no clinical follow-up
included two patients with documented extracranial
progression and one patient with combined intracranial/
extracranial progression based on reports from local
providers. In terms of dose level and availability for eva-
luation, all three level one (35 Gy) cases were evaluable
by imaging at three months. Five of 16 (31%) level two
(40 Gy) cases, 4/15 (27%) level three cases (50 Gy), 4/8
(50%) level four (55 Gy) cases and 1/6 (17%) level five
(60 Gy) were found to be non-evaluable by imaging at
three months. No statistical association between dose
level and non-evaluation rate was found to exist in this
patient population (chi square p = 0.60). That is, a simi-
lar proportion of patients were non-evaluable at each
dose level, decreasing the probability that there was an
underestimation of dose limiting toxicity due to a differ-
ence in early patient attrition at the dose levels exam-
ined. There were 2/4 patients treated at the highest dose
level (level five, total of 60 Gy lesion dose) who were not
evaluable at 3 months. One patient did have a follow-up
MRI scan prior to the three-month mark, which demon-
strated progressive CNS disease that accounted for his
death prior to the three-month clinical follow-up. The
other patient had documented progressive extracranial
metastatic disease prior to death with no neurologic
signs or symptoms to suggest treatment related toxicity.
No cases of grade III-V DLT were found to possibly,
probably, or definitely be attributable to protocol treat-
ment in any of the study cohort levels examined in the
Phase I study. Median survival of all patients was 5.29
months (range 0.49-31.2 months). Seven patients were
still alive at the time data analysis (09/09). Median fol-
low-up of all living patients was 7.72 months (range 3.4-
24.2 months). No treatment related late toxicity was
noted among this subgroup of patients. Of the 32
patients radiologically assessed at the three month per-
iod of time; 2 patients experienced a complete response,
16 a partial response, 6 demonstrated stable disease, and
8 had progressive disease, for a crude rate of stable or
responding disease of 75% (24/32). Of the 8 patients
with progression, 4 patients had local progression in the
SIB treated lesions, 2 patients had intracranial but non-
local CNS progression (i.e. outside of the SIB treated
lesions), and another 2 patients had both local and CNS
progression on 3 month imaging.
In summary, we were able to achieve our target dose
of 30 Gy WBRT with a simultaneous boost of individual
lesions up to 60 Gy, both delivered over 10 fractions.
No dose limiting toxicity at the three-month assessment
was noted at any of the dose levels and among the sub-
set of patients living beyond 3 months no treatment
related late toxicity was noted. A number of patients
enrolled on our trial missed complete follow-up (due to
lack of imaging or clinical assessment) at the three-
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month point exclusively due to extracranial, intracranial
progression or intercurrent disease. In all cases, it was
determined that this early deterioration was not due to
treatment related toxicities. In terms of patient outcome,
partial responses were seen at all dose levels, without a
clear increase in response rate with increasing SIB dose
due to the limited numbers included in this phase I
study. The three-month non-evaluable rate in our phase
I clinical study is consistent with the RTOG 9508 post-
treatment dropout rates. In addition, formal neurocogni-
tive testing or quality of life assessments were not
included in this study thus the impact of the SIB
approach in these domains remains to be demonstrated.
Formulation of phase II clinical trial
Ideally, a phase III equivalence study would be desirable
to confirm whether SIB-HT treatment as developed in
our Phase I trial is equivalent to WBRT + SRT in terms
of patient outcomes. However, a phase III equivalence
study would require a prohibitively large sample size,
which is not justifiable based on present information.
Thus, we propose that a single-arm phase II study is
warranted to ensure that efficacy outcomes with HT are
not significantly worse than what would be expected for
patients given WBRT + SRS. HT would be considered
of interest for study in a phase III equivalence trial com-
pared with WBRT + SRS if preliminary evidence indi-
cated that HT was not substantially inferior to WBRT +
SRS. However, if a phase II study indicated that efficacy
outcomes for patients given HT were significantly worse
than WBRT + SRS, than performing a phase III equiva-
lence study would not be justifiable. Thus, this phase II
study will explore whether outcomes for patients treated
with HT are significantly worse than outcomes for
patients treated with WBRT + SRS.
Methods/Design
Study objectives/hypotheses
The primary objective of interest in this study is to
obtain an estimate of median overall survival (OS), six-
month intracranial control (ICC) and six-month intrale-
sional control (ILC), in order to ensure that the fractio-
nated treatment is not substantially inferior to RTOG
historical controls. Secondary objectives include longitu-
dinal RECIST criteria response rates, cognitive assess-
ment, health-related quality-of-life, and treatment-
related toxicity.
The study null hypothesis is that fractionated HT SIB
RT is not inferior to reported RTOG 9508 SRS out-
comes of OS, ICC, and ILC. The study alternative
hypothesis is that fractionated HT SIB RT is inferior to
ANY reported historical RTOG SRS outcomes of OS,
ICC, and ILC.
Study design overview
The proposed clinical trial is designed to be a phase II
multi-institutional assessment of helical tomotherapy
simultaneous in-field boost radiation to 1-3 brain metas-
tases in patients with a variety of primary malignancies.
A common dose of the 60 Gy MTD in 10 fractions will
be used from the result of the preceding phase I dose-
escalation trial as coordinated by the London Regional
Cancer Program. No blinding or randomization proce-
dures are required in this protocol. However, maximal
accrual to the following four bins will be respected in
order to balance overall patient population with respect
to the primary site of disease as well as brain metastasis
number for an accurate historical comparison to the
RTOG stereotactic trial.
Bin #1: Lung Primary and Solitary Metastasis, n = 33
Bin #2: Lung Primary and 2-3 Metastasis, n = 19
Bin #3: Non-Lung Primary and Solitary Metastasis, n
= 26
Bin #4: Non-Lung Primary and 2-3 Metastasis, n = 15
Inclusion criteria for this research protocol will
include: a histologic diagnosis of primary cancer, a con-
trast-enhanced MRI demonstrating 1-3 metastases
within 6 weeks of study enrollment, patient age ≥ 18
years, KPS ≥ 70, patient to be available for subsequent
follow-up appointments and diagnostic testing, antici-
pated survival (independent of the brain metastases) > 3
months, patient informed consent obtained, and the
extracranial disease must be controlled, to be treated, or
absent. Exclusion criteria for this protocol will include:
metastases not suitable for synchronous boost (> 3
lesions or any lesion size > 3 cm in maximum dimen-
sion, metastases close to (within 5 mm) brainstem or
optic apparatus, cytologic or imaging evidence of lepto-
meningeal spread, intracranial extension of an osseous
(calvarial) metastasis, or evidence of intraventricular or
subependymal growth), no prior histologic confirmation
of malignancy, underlying medical condition precluding
adequate follow-up, prior cranial radiotherapy, concur-
rent cytotoxic chemotherapy, lack of informed consent,
patient unable to complete study questionnaires, and
any contraindications to MRI or gadolinium contrast.
Study endpoints and sample size calculation
The primary outcome measure of this study has been
selected after review of the literature regarding recent
(RTOG 9508 and RTOG 0614) clinical trials assessing
radiotherapy for brain metastases. The RTOG trials
have focused on overall survival and intracranial control
of disease as endpoints of interest. For example, patients
treated with WBRT + SRS on the RTOG 9508 trial
experienced median overall survival of approximately
6.5 months with 6-month intracranial tumour
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progression-free rate of approximately 85% and 6-month
local (lesion) control rate of approximately 90%.
We hypothesize HT would be considered unsuitable
for further study if the median OS for patients treated
with the HT SIB technique is degraded by 2 months, or
the intracranial progression-free rates (ICC and ILC) are
inferior by 10% or greater compared to the expected
results with treatment by WBRT + SRS. In other words
if in our phase II trial OS ≤ 4.5 months, 6-month intra-
cranial progression-free (ICC) rate is ≤ 75%, OR 6-
month local control (ICL) rate is ≤ 80%, HT SIB RT
would be considered to be inferior to the RTOG histori-
cal control data for WBRT+SRS and should not proceed
to phase III testing. To account for multiple testing,
each statistical assessment of each individual outcome
will be set at the a = 0.025 and b = 0.10 levels. All tests
will be 1-sided and calculations will be performed using
the on-line calculators available at (http://www.crab.org/
Calculators.asp - Southwest Oncology Group (SWOG)
Cancer Research and Biostatistics (CRaB) department).
It is assumed that for this study, patients will be accrued
over two years and there will be 6 months of follow-up
after the last patient is accrued. Therefore, for overall
survival, set H0: median OS = 6.5 months versus HA:
median OS = 4.5 months, 93 total patients are required.
For the ICC progression-free rate, set H0: 6-month rate
= 85% versus HA: 6-month rate = 75%, 71 total patients
are required. For ILC progression-free rate, set H0: 6-
month rate = 90% versus HA: 6-month rate = 80%, 53
total patients are required. Given the actuarial nature of
the six-month OS endpoint, no additional adjustment
for loss to follow-up is required. Thus, we will aim to
accrue a total of 93 enrolled and on-treatment patients,
as this will be sufficient to assess all outcomes of inter-
est (OS, ICC, ILC).
Logistical issues
Given the multi-institutional nature of this clinical trial,
several pre-requisites exist for centres to participate in
this clinical trial. Centres must have Helical Tomother-
apy technology available at their centre in order to parti-
cipate in this clinical trial. A copy of local REB and local
clinical trial unit approval letters must be sent to coordi-
nating centre PI prior to initiation of this study. Partici-
pating centres must submit a three metastases test case
planned with HT with phantom delivery and measure-
ment data to demonstrate the centre’s ability to deliver
protocol treatment. This three-metastasis test case will
be provided to the participating sites by the London
investigators in order to provide a relative quality assur-
ance assessment of the various participating centres.
This planning and phantom data will require quality
assurance approval by physics PI prior to clinical trial
initiation and patient enrolment. In conjunction with
this physics submission, all default planning importance,
penalty factors, and precedence factors to be submitted
to and approved by coordinating centre PI. Any
required modifications to the protocol, letter of informa-
tion, consent form, and/or local case report forms need
to be approved by coordinating centre prior to patient
enrolment to ensure compatibility with the central study
database.
Study procedures
All patients must have a contrast enhanced MRI brain
within six weeks of study enrolment, a dictated history
including steroid and anti-convulsant usage, dictated
physical examination, screening neurological examina-
tion with mini-mental status examination (MMSE),
FACT-Br HRQoL questionnaire completed during
enrolment visit, and a baseline NCI-CTC V3 toxicity
assessment. All medications received by the study sub-
jects prior to initiation will be recorded on the subject’s
case report form. Specific treatment simulation and
planning details with relation to the delivery of 60 Gy
SIB with 30 Gy WBRT are available in the attached clin-
ical protocol (see Additional file 1). Steroid, anticonvul-
sant use and cancer therapies/medications delivered
after treatment initiation will be recorded. Cytotoxic
chemotherapy is not permitted during the radiotherapy.
Patients may be treated with glucocorticoids and pro-
phylactic anticonvulsants as required.
Follow-up visits and assessments (KPS, NCI CTC V3
Toxicity, FACT-Br HRQoL, steroid, and anticonvulsant
medications) will occur at the following intervals post
treatment: 6 weeks and 3, 6, 9, 12, 18, and 24 months.
Contrast enhanced MRI brain scans will occur at 3 and
6 months after radiation therapy completion. Other CT
or MRI based imaging will occur thereafter according to
institutional standard of care guidelines prior to subse-
quent visits. Participating centers will be required to
declare their standard of care imaging past 6 months to
the study principal investigator prior to patient
enrolment.
Statistical analysis plan
Descriptive statistics will be used to summarize the
patient population, tumor- and treatment-related para-
meters, treatment toxicities, causes of death, location of
intracranial, intralesional and extracranial progression
and performance status. Time to event outcomes will be
estimated using the Kaplan-Meier method. Tables and
plots will be used to better illustrate results. 95% confi-
dence intervals will be constructed for outcomes of
interest. A calculation of actuarial six-month OS, ICC,
and ILC will be performed after all patients have had 6
months of potential follow-up in order to assess the
phase II research question to either accept or reject the
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study hypothesis that HT SIB RT is a clinically appro-
priate alternative to WBRT+SRS.
Discussion
Knowledge dissemination plan
Successful completion of this phase II clinical trial will
allow for a publication regarding the clinically significant
outcomes, related to fractionated HT-based radiosur-
gery, such as overall survival, intracranial control, and
local intralesional control. Venues for publication
include the various primary radiation oncology journals
and presentations can occur at national oncology meet-
ings such as the Canadian Association Radiation Oncol-
ogists, American Society of Therapeutic Radiation
Oncology, and the American Society of Clinical Oncol-
ogy. Presentations at other meetings including brain and
supportive care specific conferences can further dissemi-
nate any scientific information gained from this research
program. Subsequent presentations to cooperative
groups (e.g. RTOG, NCIC) with respect to a formal
phase III study will depend on the results reported with
respect to this study.
Potential study obstacles
The main obstacle that potentially may interfere with
successful completion of this trial is low patient accrual.
Ongoing monitoring of accrual will be performed in
order to continually assess this issue. Accrual updates
will be performed to all participating institutions in
order to maximize the exposure of this study. Further
review of inclusion/exclusion criteria may be necessary,
in future, to ensure that barriers to appropriate enroll-
ment of patients are minimized.
Study timelines
November 2009: OICR Grant Application Complete
January 2010: REB Approval at LHSC Obtained
(UWO REB 16776)
Spring 2010: OICR Research Funding Confirmed
(09NOV-259)
Spring 2010: Initiation of Clinical Protocol at LHSC
site
July 2010: REB Approval and Protocol Initiation at
Other Participating Institutions
June 2013: Expected Completion of Accrual
January 2014: Six-month Follow-up Completed*
February 2014: Data analysis of Primary Endpoint
Completed*
Spring 2014: Abstracts Completed for National
Meetings*
Fall 2014: Research Presentations, Preparation of
Manuscripts on Phase II Study*
*Depending on actual date of accrual completion.
Investigator team
The principal investigator of this project will be ulti-
mately responsible for the conduct of the clinical trial.
GR has been awarded a clinician scientist designation
through the Ministry of Health Ontario-Ontario Asso-
ciation of Radiation Oncologists program that allows for
dedicated research time to ensure the proper supervi-
sion of this research to its completion. GB (Radiation
Oncologist, coinvestigator) has extensive clinical and
research experience with helical tomotherapy and CNS
tumours. SY is a coinvestigator in the area of medical
physics and helical tomotherapy who will provide phy-
sics support for the dosimetric and clinical trial compo-
nents of this research program. KT (Neuroradiologist)
will provide support for interpretation of CNS response/
relapse determination.
Participating sites
Participating site collaborators from Ottawa, Montreal-
CHUM, Montreal-McGill, and Edmonton will coordi-
nate the activation of this clinical trial at all their
respective TomoTherapy centres. This clinical trial will,
therefore, be the broadest Canada-wide HT collabora-
tion since clinical implementation of HT in 2003. In
addition, ongoing external collaborations with non-parti-
cipating sites (primarily Dr. F Lagerwaard - VU Amster-
dam) will augment our capability for innovative
hypothesis generation with relation to oligometastatic
brain disease (1-3 vs. > 3 mets), fractionation selection
(5 versus 10 fractions), and radiation platform selection
(Tomotherapy® versus RapidArc®) as well as other
hypotheses. Although this institution is not formally
part of the phase II protocol, this external collaboration
may assist in the eventual design, implementation, and
successful completion of a future definitive phase III
clinical trial [20].
Additional material
Additional file 1: Clinical Trial Protocol.
Abbreviations
BED: Biologically effective dose; Br: Brain; C: Cervical; CNS: Central nervous
system; CONSORT: Consolidated standards of reporting trials; CT: Computed
tomotherapy; CTC: Common toxicity criteria; DLT: Dose limiting toxicity;
FACT: Functional assessment of cancer therapy; GTV: Gross tumor volume;
Gy: Gray; HRQoL: Health-related quality-of-life; H0: Null hypothesis; HA:
Alternative hypothesis; HT: Helical tomotherapy; ICC: Intracranial control; ILC:
Intralesional control; IMRT: Intensity modulated radiation therapy; KPS:
Karnofsky performance status; L: Left; LQE: Linear quadratic equation; MMSE:
Mini-mental status examination; MRI: Magnetic resonance imaging; MTD:
Maximum tolerated dose; NCI: National cancer institute; OS: Overall survival;
PI: Principal investigator; R: Right; REB: Research ethics board; RECIST:
Response evaluation criteria in solid tumors; RTOG: Radiation therapy
oncology group; SIB: Simultaneous infield boost; SRS: Stereotactic
radiosurgery; Sx: Surgery; WBRT: Whole brain radiation therapy.
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